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Surface-based Microfluidic Systems for Enhanced Biomarker De-
tection
The 21st century has seen a surge in the development of point-of-care (POC) testing sys-
tems integrated with microfluidic bioassay devices, for portable, fast, and user-friendly
disease diagnostics. These systems detect diagnostic biomarkers from a small quantity
of the patient’s blood plasma, by exploiting their innate nature to bind to specific
receptor molecules. A microfluidic bioassay device is considered to be of “high effi-
ciency” when low biomarker concentrations (1 pM–1 nM) can be detected within a few
minutes. This thesis explores the collective influence of surface chemistry, biomarker
transport and biomolecular reactions at the microscale, to propose design principles for
the development of rapid, sensitive and user-friendly fluorescence-based POC systems.
First, we exploit radio-frequency air plasma to covalently tether receptor proteins
within polymethyl methacrylate microfluidic bioassay devices, at high-throughput.
Next, these devices are integrated with a palm-sized modular Fluid Handling Device
that allows precise mixing, filtration, and delivery of fluids, for subsequent detection
of Chlamydia trachomatis specific antibodies, with a limit of detection (LoD) of 7 nM
within 15 mins, serving as a “proof-of-concept” POC testing device.
Next, biomarker transport-dependent kinetic enhancements in microfluidic bioassay
systems are investigated using novel 3D glass devices, where real-time binding events
between varying concentrations of fluorescently-labelled receptor and ligand antibodies
are analyzed. Combing experimental measurements with scaling analysis, two key
control dimensionless parameters are proposed to achieve “rapid” and “sensitive” ligand
detection: a local Peclet number Peδ that characterizes the balance between local
convection and diffusion-driven transport of ligands; and a kinetic Damkohler number
(Dakinetic) that characterizes the balance between the rates of receptor–ligand binding
and convection-driven ligand replenishment. We observe that homogeneous ligand
binding can be achieved by decreasing the depletion layer thickness (< 5 µm) with
enhanced local convection at Peδ >> 105. At Dakinetic << 10−2, we demonstrate that
enhanced convective ligand replenishment leads to quenching of transport limitations,
thereby enhancing the speed of ligand detection at the molecular limit. Finally, we
validate that rapid (detection time of 10 mins) and sensitive (LoD of 11.63 pM) ligand
detection can be achieved in microfluidic systems with Peδ >> 107 for Dakinetic <<
10−2. With prior knowledge of the kinetic constants, these design principles can be
applied to various biomolecular systems, paving way to creating highly efficient POC
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Point-of-care disease diagnostic systems
The emphasis on early disease diagnosis and treatment has spurred the development
of new technologies aimed at creating faster, reliable and affordable disease diagnos-
tic systems. While economically developed countries are known to be more open to
adopting new technologies, resource-limited countries still rely on obsolete technologies
due to the low economic stability, and lack of infrastructures and trained personnel.
To address these challenges, point-of-care (POC) devices are being developed to serve
as cheap, portable, user-friendly, yet reliable disease diagnostic platforms for a wide
variety of diseases ranging from metabolic to infectious diseases [5–7].
The versatility of the POC systems enables their use in different environments,
to detect a wide range of disease “biomarkers” for both diagnostic and disease mon-
itoring applications. Here, the “biomarkers” are typically proteins, chemical analytes
or metabolic markers present in a patient’s blood, saliva or urine, that are indicative
of the patient‘s health. These biomarkers exist at homeostatic concentrations under
normal conditions, while their concentrations fluctuate from these levels when the pa-
tient is afflicted with a disease. Disease diagnosis can be performed by first isolating
Figure 1: Schematic of a point-of-care (POC) device. Illustrative description of
the components of a typical POC device that is capable of processing a biological fluid
sample (e.g., blood), perform biochemical analysis to detect diagnostic biomarkers and
display the results, in an integrated platform.
1
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and purifying the biofluid sample, and then detecting the presence or absence of the
disease-specific biomarkers in the biofluid [8–10].
Typically, POC systems are designed to serve as all-inclusive platforms capable of
processing the biofluid samples, performing biochemical analysis to detect the biomark-
ers in the processed fluid, and display the detection results (Figure 1), within a short
period of time, typically within 30–60 mins [11]. While the portability and speed of the
integrated systems are attractive features, the adoption of these systems in healthcare
facilities is determined by the “sensitivity” and “specificity” of the biomarker detection.
Microfluidic bioassay devices are currently being incorporated into the POC systems
for further miniaturization, to allow for the development of rapid yet sensitive and well-
controlled biomarker detectors, with limited sample and reagent volume requirements.
Microfluidic bioassay devices
Since the early 1980’s, microfluidic systems have significantly evolved to enable
the creation of cheaper, faster and more reliable means for simultaneous biochemical
analysis of multiple biomarkers [12–14]. These systems consist of networks of microscale
channels that enable enhanced transport of biomarkers in the biofluids for subsequent
biochemical reactions with specific capture molecules (Figure 2).
Advances in microfabrication techniques have allowed for the fabrication of mi-
crofluidic devices using a wide range of materials. Low-cost poly-(dimethylsiloxane)
(PDMS)–glass hybrid devices are generally employed for laboratory scale analysis.
These devices are easy to fabricate, optically transparent and allow for detection of
Figure 2: Schematic of a surface-based microfluidic bioassay device. A solu-
tion of biomarkers (green stars) are flowed through a microchannel consisting of immo-
bilized receptors (blue sticks) on the bottom wall of the channel. The biomarkers react
with the immobilized receptors when in close proximity, to complete the biochemical
assay reaction.
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biochemical reactions using conventional microscopy techniques. However, the high
susceptibility of channel deformation at high flow rates, makes PDMS–glass devices
less compatible for fast flows [15, 16]. On the other hand, novel selective laser-induced
etching (SLE) processes has allowed for the fabrication of truly 3-dimensional (3D)
microfluidic systems embedded in glass substrates [17]. While these systems are able
to withstand fast flows and allow for the optical detection of biochemical reactions,
they are not amenable to large scale processing. To enable high-throughput fabrica-
tion of microfluidic devices with the desired optical traits of the glass-based systems,
polymeric substrates such as polymethyl methacrylate (PMMA), polycarbonate, etc.,
are increasingly employed in POC systems [18, 19].
Irrespective of the material of the microfluidic device, the biofluids are transported
through the channels by one of many active fluid delivery processes such as pressure-
driven flow, electrokinetic flow, centrifugal flows, or by passive methods such as capil-
lary flow [20]. While different applications benefit from different modes of fluid delivery,
pressure-driven flow proves to be the most beneficial for automatized microfluidic bioas-
say systems, as it enables continuous and sequential delivery of reagents with better
control over flow parameters throughout the process [21]. Additionally, flow in these
systems is laminar, i.e., the biomarker-rich biofluids are transported in independent par-
allel layers without mixing. This makes the fluid transport through these systems easy
to predict with the help of well-defined analytical models [22]. As a consequence, fast
and reagent-friendly microfluidic systems can be designed by simply optimizing those
parameters that have a significant influence on the biochemical reaction employed to
detect the biomarkers.
Surface-based receptor–ligand bioassays:
The process of detecting biomarkers in a microfluidic bioassay device relies on the
biochemical reaction between biomarker ligands and complimentary receptor molecules.
Here, the receptor molecules are generally proteins such as antibodies [23], or DNA
fragments such as aptamers [24], that are capable of recognizing and binding to specific
biomarker ligands. These receptor–ligand recognition reactions are highly specific,
thereby enabling the detection of the disease biomarkers with high-specificity.
Surface-based systems are frequently used to perform these biochemical analyses,
where the biomarker ligands are flowed in solution through the microfluidic channels
coated with receptor molecules on one or more surfaces of the channels (Figure 2). Here,
the receptor–ligand reaction occurs on the solid–liquid interface in the microfluidic
channel [25]. At the microscale, the ligands are in increasingly close proximity to the
channel walls thereby increasing the probability of the receptor–ligand interactions
in microfluidic systems. Due to the large surface-to-volume ratios in the microfluidic
systems, the speed of the receptor–ligand reaction is enhanced, with drastically reduced
reagent volumes required for the entire process [23].
While the geometrical scale of the microfluidic channel plays an important role in
the speed of the ligand detection, the sensitivity of the system is determined by the
density, biofunctionality and orientation of the immobilized receptors [26].
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Surface chemistry for immobilization of receptors:
Receptor immobilization, is the fundamental process that affects the “sensitivity”
of the surface-based microfluidic bioassay systems. For this purpose, different surface
functionalization strategies have been proposed depending on the material used to fabri-
cate the microfluidic devices. The common goal of all the functionalization strategies is
to enable covalent immobilization of the receptor molecules, such that the receptors are
able to withstand the high flow rates experienced on the channel walls. Most commonly
employed covalent immobilization strategies are based on coupling chemistries that ini-
tiate an amide bond (CONH) between amine (NH2) and carboxylic acid (COOH)
moeities [27, 28]. Of the available coupling chemistries, two of the most commonly
used chemistries are (i) 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-
Hydroxysuccinimide (NHS) chemistry, and (ii) bis(sulfosuccinimidyl)suberate (BS3)
chemistry. EDC is a carbodiimide that reacts with the COOH groups either present
on biomolecule surfaces [28], or on the material surface, to form a highly reactive ester
intermediate. This ester then reacts with the available NH2 groups on the substrates,
or biomolecule surfaces to form the final amide bond. Here, NHS is used to stabilize
the ester during the conjugation process [29]. Conversely, BS3 is an amine to amine
[NH2 to NH2] crosslinker [30] which is a water soluble analog of NHS.
Regardless of the functionalization strategy, utmost care must be taken to ensure
that the surface manipulations do not disrupt the conformations of receptors [31]. In
addition, the surface coverage or density of the receptors has shown to be another key
parameter that influences the receptor–ligand reaction efficiency [32].
Existing techniques used to pattern biomolecules on glass and polymeric surfaces
at the micro- and nanoscales, include physical patterning approaches such as pho-
tolithography [33], adsorption of biomolecules confined to microfluidic networks [34],
and colloidal lithography [35]. These techniques are either plagued by high costs, low
throughput, or have limited control over the geometry and functional properties of the
immobilized receptors.
Microcontact printing:
On the contrary, microcontact printing (µCP) [36–38] has been preferentially used
to immobilize biomolecules in well-defined patterns on a wide range of substrates. Dur-
ing this process, a liquid solution containing receptor molecules are inked on micropat-
terned elastomeric PDMS stamp surfaces. After incubation, the stamps are washed,
dried and stamped onto a substrate with higher surface energy than that of the stamp
(Figure 3). This causes the transfer of the inked molecules from the stamp to the
substrate.
Although these microcontact printed biomolecules have been successfully incorpo-
rated into microfluidic devices [39, 40], several challenges remain. First, as patterned
biomolecules are physically adsorbed onto the surfaces driven by hydrogen-bonding and
van der Waals forces [41], they are unable to withstand high shear stresses introduced
by the flow present in microfluidic channels. As a result, it gives rise to gradual desorp-
tion and degradation of patterned biomolecules that lead to reduced device performance
and poor shelf life. Secondly, since partial dehydration of biomolecules is a prerequisite
to the µCP technique, the probability of protein denaturation and impaired biological
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Figure 3: Schematic of the microcontact printing process. A receptor solution
is deposited on a micropatterned PDMS stamp. The incubated stamp is washed and
dried before transferring the receptors via stamping onto a higher energy substrate.
activity is high. Lastly, patterning a substrate with multiple biomolecules proves to be
difficult and time-consuming, as each individual stamp can only be utilized to pattern
a single ink at a time.
Nevertheless, there is immense potential to incorporate microcontact printing for
patterning surfaces with linkers such as silanes [42], that enable subsequent coupling
of biomolecules. This ensures the preservation of biomolecule functionalities, with
the added advantage of covalent coupling to surfaces which enable biomolecules to
withstand the high flow rates in the surface-based microfluidic devices.
Fluorescence-based detection:
Following receptor immobilization, the microfluidic bioassay system is primed to
capture biomarker ligands from the biofluid. However, suitable detection methods
are required to detect the receptor–ligand reactions occurring in the systems. The
commonly employed detection methods are holistically divided into two families: (i)
label-free and (ii) label-based detection strategies [43]. Label-free strategies rely on the
direct detection of receptor–ligand reactions occuring on metallic thin films or nanos-
tructure, by monitoring the changes in surface mass adsorption. The most commonly
used label-free detection strategies rely on optical sensing of mass dependent surface
electron resonance energy changes using surface plasmon resonance (SPR) and local-
ized surface plasmon resonance (LSPR) sensors [44–46], or direct detection of mass
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variation using quartz crystal microbalance (QCM) [47, 48]. While these sensors have
been shown to be highly sensitive to detect small changes in concentrations, they re-
quire complex instrumentation making it difficult to integrate within a microfluidic
chip.
On the other hand, more conventional label-based detection strategies such as col-
orimetric detection [49] and fluorescence detection [50], rely on commonly used imag-
ing instruments such as absorbance readers and microscopes. Owing to the ease of
integration with microfluidic bioassay systems, fluorescence-based detection has been
the preferred detection strategy, both at the laboratory and industrial settings. Us-
ing this strategy, the receptor–ligand reactions are detected with the help of tertiary
fluorescently-labelled detection molecules that are specific to the ligands. In a typical
fluorescence-based surface bioassay, the fluorescently-labelled detection molecules are
flushed through the channels after the receptor–ligand reaction is completed. Subse-
quently, the changes in fluorescence intensity are monitored via fluorescence microscopy.
Here, the fluorescence intensity is proportional to the concentration of ligands captured
in the bioassay system, based on the Beer-Lambert law [51]:
F = kI0φ[1− (10−εbc)], (1)
where, F is the fluorescence intensity, k is the proportionality constant related to
the instrument, I0 is the intensity of incident light, φ is the fluorescence quantum yield,
ε is the molar absorptivity of the molecule (L/mol.cm), b is the path length and c is the
concentration of the molecule (moles/L). In typical fluorescence-based bioassays, dilute
solutions of fluorescently-labelled detection molecules are employed. As a consequence,
it is assumed that only <2% of the excitation energy is absorbed, resulting in the
simplified equation 2:
F = kI0φεbc. (2)
This relationship that shows that the analyte concentration is proportional to the
fluorescence intensity, serving as the foundation of quantitative analyses in fluorescence-
based bioassays.
Kinetic enhancements:
While the “sensitivity” of the microfluidic bioassay systems is determined by the
biofunctionality of the immobilized receptors, the “biomarker detection speed” is influ-
enced by the operational and geometric characteristics of the device. Several previous
studies have demonstrated that mass transport limitations are common problems ob-
served in surface-based bioassay devices [26]. These limitations arise when the ligands
are depleted from the solution by the receptor-coated surface, at a rate faster than the
rate at which the ligands are replenished by the flowing solution.
Several reports have indicated that receptor–ligand reaction kinetics can be en-
hanced using microfluidic bioassay systems as a result of the reduced length scales.
Specifically, authors have reported the influence of several microfluidic operational and
geometric variables on the ligand detection speed. Ekins et. al., showed that the lig-
and capture rate increased significantly with decreasing size of the reaction site [52].
7
Several following reports corroborated these observations, proving a proportional rela-
tionship between the size and geometry of the reaction sites containing the immobilized
receptors and the receptor–ligand reaction kinetics.
In parallel, the aspect ratio of the microfluidic channels was shown to significantly
influence the receptor–ligand kinetics. Specifically, authors demonstrated that mi-
crofluidic channels with rectangular cross-sections resulted in faster ligand detection
rates when compared to square microchannels [53]. Additionally, Lynn et. al., showed
that the efficiency of ligand capture in microfluidic systems scales inversely with the
microchannel height [54].
These experimental observations of receptor–ligand reaction kinetic enhancements
in microfluidic bioassay devices were explained to be a consequence of modified lig-
and transport to the reaction site, resulting from the combined effect of length scale
reduction at micron and sub-micron scales, and enhanced ligand transport in these
systems.
With the help of scaling analyses, well-established analytical models have attempted
to encapsulate various inter-dependent variables into several dimensionless parameters
to provide order-of-magnitude comparisons between competing phenomena, i.e., con-
vection, diffusion and reaction. Depending on the rate-limiting time scale, the microflu-
idic devices commonly operate in convection-limited, diffusion-limited, or reaction-
limited regimes. Diffusion-limitations are commonly observed in static and high flow
rate microfluidic systems, where the biomarker detection time is purely determined
by the time taken for the biomarker molecules to diffuse to the receptor-coated sur-
faces [55, 56]. On the other hand, convection-limitations are commonly observed in
nanofluidic systems, where the biomarkers are able to diffuse to the receptor-coated
surfaces faster than they are convected through the channels, due to reduced length
scales [57]. Diffusion and convection-limitations, collectively termed as “mass-transport
limitations”, have been described to contribute to the low biomarker detection speeds
in surface-based bioassay systems. Current efforts are focused on developing reaction-
limited bioassay systems, where the rate of ligand transport to the receptor-coated
surface is faster than rate of receptor–ligand reaction. In this desired regime, the
biomarker detection speed is solely determined by the innate kinetic properties of the
receptor–ligand binding reaction [26].
Researchers have proposed design rules to help engineers develop reaction-limited
microfluidic bioassay systems by enhancing convective ligand transport to the receptor-
coated surfaces [26, 58, 59]. However, the applicability of these design rules under
extremely fast flows is still unclear.
Biomarkers
Green fluorescent protein (GFP):
Green fluorescent protein (GFP) was first isolated from the bioluminescent jellyfish
Aequorea victoria for its intrinsic property to exhibit green fluorescence when exposed
to blue light. This intrinsic fluorescing property is attributed from the ability of the
protein to naturally form internal chromophores encapsulated within cylindrical pep-
tide barrels. Owing to the sensitivity of the protein structure to changes in pH, ionic
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strength and temperature of the environment, GFP has been extensively exploited in
biotechnology applications [60, 61]. Most importantly GFP has served to be benefi-
cial in surface chemistry studies where changes in surface chemistry-mediated protein
conformations can be easily monitored by detecting fluorescence quenching due to de-
generation of GFP structure. Additionally, fluorescence-based receptor–ligand binding
kinetics can be easily monitored without the need for the tertiary fluorescently-labelled
molecule, due to the innate fluorescing properties of the GFP molecules.
Immunoglobulin G (IgGs):
When a person is afflicted with a bacterial, viral or fungal infection, the person’s
immune system secretes factors called antibodies or immunoglobulins (Ig), to neutralize
those pathogens. Depending on the type of infection, various kinds of immunoglobulins
such as immunoglobulin A (IgA), M (IgM), G (IgG), etc. are circulated around the
body via the patient‘s blood. Each Ig has a different role during the process of com-
bating the pathogen. Immunoglobulin G (IgG) is the most common type of antibody,
constituting almost 75% of the antibodies in the patient blood. In addition to aiding
in the lysis of the invading pathogen, IgGs provide long-term immunity against the
pathogen, protecting the patient from further infections. As a result, these molecules
have served as prognostic biomarkers, where their detection provides information about
the patient’s state of infection and recovery [62].
For example, clinical research has shown that bacterial Chlamydia trachomatis in-
fections are the most prevalent sexually transmitted infection in the world [63]. As
these infections are asymptomatic, they lead to a continued widespread of the infection.
Additionally, this bacterial infection has been identified to cause pelvic inflammatory
diseases (PID), infertility and miscarriages in women. Clinicians diagnose these pa-
tients by performing antibody tests from the patient blood in order to quantify the
IgGs specific to protein fragments of C. trachomatis, such as major outer membrane
protein (MOMP) [64, 65]. In addition, with the help of genetic engineering, standard
IgGs have been fluorescently labelled to allow researchers to study and develop IgG
bioassay systems for a wide range of diseases.
Interleukin-6 (IL6) and C-reactive protein (CRP):
Interleukin-6 (IL6) [66, 67] and human C-reactive protein (hCRP) [68, 69] have
been known to be the most important biomarkers of neurological, cardiovascular and
other pathophysiological conditions that arise from tissue inflammation or infection.
Quantitative detection of these biomarkers has immensely helped in early diagnosis
and treatment of these diseases. For accurate disease diagnostics, sensitive assays
and biosensing technologies are required to reliably detect minute quantities of these
biomarkers [8, 70]. In addition, as these molecules have been well-characterized over
the years, bioengineers are equipped with detailed molecular information that allows
them to fabricate bioassay systems for sensitive detection of CRP and IL6 with the
help of complimentary receptor antibodies (proteins) or DNA aptamers.
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Thesis outline
The centralized aim of this thesis is to propose design principles for the development
of rapid and sensitive point-of-care disease diagnostic platforms. To demonstrate the
versatility of the proposed principles, each process discussed in this thesis was tested
on a wide range of biomarkers. As illustrated in Figure 4, the thesis is broken down
into four chapters, where each process is elaborated as a separate chapter.
In Chapter 1, we present a high-throughput functionalization strategy for the de-
velopment of polymethyl methacrylate (PMMA) microfluidic bioassay devices. Specif-
ically, we demonstrate the generation of functional COOH groups on the surfaces of
PMMA using radio-frequency (RF) air plasma. These COOH groups subsequently
serve as functional sites for covalent adhesion of proteins such as green fluorescent
protein (GFP) and major outer membrane protein (MOMP) of Chlamydia trachoma-
tis, via 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), N-hydroxysuccinimide
(NHS) chemistry. The functionalized surfaces are then incorporated into microfluidic
devices to enable the detection of clinically significant concentrations of Chlamydia
trachomatis-specific immunoglubulin G (IgGs).
Figure 4: Illustrative overview of the thesis. The thesis is broken down into four
distinct chapters that address different experimental steps involved in attaining the
centralized goal, i.e., the development of a point-of-care disease diagnostic platform.
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These developed PMMA microfluidic bioassay devices are integrated with a novel
fluid handling device (FHD) in Chapter 2, to demonstrate a proof-of-concept point-of-
care testing device. The integrated module allows for the collection of a fluid sample,
mixing with detection antibodies, delivery to the PMMA microfluidic bioassay devices
and detection of C. trachomatis-specific IgGs via fluorescence microscopy.
To address issues regarding sample volume requirements and sensitivity of the mi-
crofluidic device, we then focus on understanding the fundamentals of flow-dependent
receptor–ligand reaction kinetics. In Chapters 3 & 4, we employ glass-based microflu-
idic devices to allow for better control of geometrical and flow parameters in this study.
In Chapter 3, we present a microcontact printing enabled bio-functionalization strategy
that allows the covalent immobilization of IgGs within glass-based microfluidic devices.
The immobilized IgGs retain their ability to capture biomarkers such as C-reactive pro-
tein (CRP) and interleukin 6 (IL6), following the immobilization process.
In Chapter 4, this functionalization strategy is used to fabricate robust 3D mi-
crofluidic bioassay devices capable of generating high shear flows. These devices are
used to investigate the validity of the proposed design design rules that have been
used as a universal standard to study microfluidic bioassay systems, since the early
2000’s. Specifically, we critically analyze their validity when applied to systems re-
lying on extremely fast flows. First, we re-examine the scaling analyses proposed by
the previous models to validate the observed experimental results. Next, we proposed
modified design rules to allow for fabrication of fast yet sensitive systems. Finally, we
use the new design rules to fabricate devices that enable the detection of a wide range







(Originally published as [2])
1.1 Introduction
Miniaturized systems, such as integrated microarray and microfluidic devices, are
constantly being developed to satisfy the growing demand for sensitive and high-
throughput bio-chemical screening platforms, by exploiting in-vitro receptor–ligand
interactions. Owing to its recyclability, and robust mechanical and optical properties,
poly(methyl methacrylate) (PMMA) has become the most sought after material for
the large-scale fabrication of lab-on-a-chip platforms. However, the chemical inertness
of PMMA entails the use of complex chemical surface treatments for covalent immo-
bilization of receptor proteins. In addition to being hazardous and incompatible for
large-scale operations, conventional bio-functionalization strategies pose high risks of
compromising the biomolecular conformations, as well as the stability of PMMA.
In this chapter (as published in [2]), we discuss the coupled effect of radio
frequency (RF) air plasma and standard 1-ethyl-3-(3-dimethylaminopropyl) carbodi-
imide (EDC), N-hydroxysuccinimide (NHS) chemistry, to achieve a simple yet scalable
PMMA functionalization strategy for covalent immobilization (chemisorption) of pro-
teins. By utilizing green fluorescent protein (GFP) as a model system, we demonstrate
that the surface density of chemisorbed proteins is shown to be highly dependent on
the air plasma energy, initial protein concentration and the buffer pH. Here, a max-
imum GFP surface density of 4 × 10−7 moles/m2 is obtained, when chemisorbed on
EDC–NHS activated PMMA exposed to 27 kJ of air plasma, at pH 7.4.
Furthermore, antibody-binding studies validate the preserved biofunctionality of
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the chemisorbed receptor GFP molecules. Finally, the coupled air plasma and EDC–
NHS PMMA bio-functionalization strategy is used to fabricate microfluidic antibody
assay devices to detect clinically significant concentrations of Chlamydia trachomatis
specific antibodies. Thus, we elucidate the potential of fabricating sensitive, repro-
ducible and sustainable high-throughput protein screening systems, without the need
for harsh chemicals and complex instrumentation.
1.2 Published Article
Shivani Sathish, Noriko Ishizu, and Amy Q. Shen. "Air plasma-enhanced covalent
functionalization of poly(methyl methacrylate): high-throughput protein immobiliza-
tion for miniaturized bioassays." ACS Applied Materials & Interfaces. 11.49 (2019):
46350-46360 [2].
1.3 Conclusions
In this chapter, radio-frequency (RF) air plasma was exploited to covalently tether
receptor proteins within poly(methyl methacrylate) (PMMA) microfluidic bioassay
devices at high-throughput. We observed that 27 kJ of air plasma generated car-
boxyl (COOH)-rich PMMA surfaces with the highest affinity towards a wide range
of receptor proteins, namely, immunoglobulin G (IgGs), streptavidin and major outer
membrane proteins (MOMP) of Chlamydia trachomatis, when coupled with 1-ethyl-
3-(3-(dimethylamino)propyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS)
chemistry, at a pH of 7.4. These receptor-coated PMMA devices served as effective
microfluidic bioassay systems to capture and detect complimentary ligand antibodies.
The rapid and scalable, yet controlled bio-functionalization method serves as a
benchmark platform to fabricate reproducible, high-throuphput protein screening sys-
tems, further driving innovations in chemical and bio-chemical screening assays. In the
following chapter, we discuss the integration of the developed MOMP-functionalized
PMMA microfluidic antibody chips, with a modular Fluid Handling Device (FHD)
to serve as a “proof-of-concept” manually operated point-of-care (POC) device for the
detection of anti-MOMP (chlamydia) immunoglobulin G (IgG) antibodies.
Chapter 2
“Proof-of-concept modular fluid
handling prototype integrated with
microfluidic biochemical assay
modules for point-of-care testing”
(Originally published as [1])
2.1 Introduction
Over the past decades, point-of-care testing kits have been developed to circumvent
the reliance on laboratories, by allowing users to perform preliminary health or envi-
ronmental testing from the privacy of their homes. However, these kits heavily rely on
the precision of the user to perform the procedures, leading to increased variability in
final assessments.
In this chapter (as published in [1]), we present an integrated, completely sealed
and disposable point-of-care testing prototype that exploits the benefits of microfluidics
and 3D-printing fabrication techniques. The palm-sized modular prototype consists of
a manually-operated Fluid Handling Device that allows precise mixing, filtration and
delivery of fluids to an on-board microfluidic assay unit (discussed in Chapter 1), for
subsequent detection of specific biochemical analytes, with minimized risk of contami-
nation and reduced user-induced errors..
2.2 Published Article
Shivani Sathish, Kazumi Toda-Peters, and Amy Q. Shen. "Proof-of-concept modular
fluid handling prototype integrated with microfluidic biochemical assay modules for
point-of-care testing." View 1.1 (2020): e1 [1].
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2.3 Conclusions
In this chapter, we presented a palm-sized modular Fluid Handling Device (FHD) that
allowed precise mixing, filtration, and delivery of fluids to the PMMA microfluidic
bioassay devices presented in Chapter 1. These integrated systems enabled the de-
tection of C. trachomatis specific antibodies, with a limit of detection (LoD) of 7 nM
within 15 mins, serving as a “proofof-concept” manually operated point-of-care (POC)
testing device.
We discussed the development of proof-of-concept microfluidic POC bioassay sys-
tems in Chapters 1 & 2. Although we achieved the detection of clinicially significant
concentrations of antibodies within 15 minutes using the developed devices, issues re-
garding sample volume requirements and sensitivity of the microfluidic assay modules
were observed.
In the following chapters, we delve into the fundamentals of microfluidic biochemical
reactions to investigate those parameters that influence the sensitivity, speed and vol-
ume requirements of the devices. We diverge from thermoplastic microfluidic systems,
and focus on more traditional glass-based microfluidic systems that are easy to inte-
grate with conventional fluorescence microscopes and are able to withstand high flow
rates without leakage. Additionally, glass substrates are naturally more hydrophilic
than thermoplastic substrates, and can be easily chemically modified to enable cova-
lent protein immobilization. The hydrophilic nature of glass surfaces ensures reduced
non-specific adsorption of proteins, thereby increasing specificity of the biochemical
reactions. In what follows, we will first describe a simple surface functionalization
technique to pattern proteins on glass substrates, followed by a novel glass 3d printing
technique that allows us to fabricate robust 3-dimensional microfluidic channels. These
glass-based microfluidic systems are used to investigate the dynamics of biochemical
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3.1 Introduction
The sensitivity of a microfluidic bioassay system is primarily determined by the bio-
functionalities of the patterned receptor biomolecules. Consequently, the primary goal
in developing a robust glass-based microfluidic system is to identify techniques that
enable efficient biomolecule immobilization whilst preserving their innate functionali-
ties.
In this chapter (as published in [4]), we discuss a two-step aqueous aminosilane
patterning approach to create covalently immobilized micro- and nanoarrays of recep-
tor biomolecules within microfluidic devices. By replacing the conventional organic
inking solvent with water, and by enforcing short incubation and contact times, we
minimize the diffusion of (3-aminopropyl)triethoxysilane (APTES) into the elastomeric
poly(dimethylsiloxane) (PDMS) stamp to preserve the pre-defined patterned features.
These APTES patterns are subsequently coupled with different receptor molecules
within microfluidic bioassay devices to carry out an aptamer-based immunoassay to
detect interleukin 6 (IL6) and an antibody-based immunoassay for the detection of
human c-reactive protein (hCRP).
3.2 Published Article
Shivani Sathish*, Sébastien G. Ricoult*, Kazumi Toda-Peters, and Amy Q. Shen. "Mi-
crocontact printing with aminosilanes: creating biomolecule micro-and nanoarrays for
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3.3 Conclusions
In this chapter, we introduced a simple aqueous based microcontact printing (µCP)
method to pattern arrays of (3-aminopropyl)triethoxysilane (APTES) on glass sub-
strates, with feature sizes ranging from a few hundred microns down to 200 nm (for
the first time). Next, these substrates were integrated with microfluidic channels, to
covalently couple DNA aptamers and antibodies with the micro- and nanopatterned
APTES. As these receptors are covalently tethered to the device substrates, the result-
ing bonds enable them to withstand the high shear stress originated from the flow in
these devices. We further demonstrated the multiplexing flexibility of this technique,
by immobilizing multiple receptor proteins onto these APTES-patterned substrates us-
ing liquid-dispensing robots. Next, to validate the functionalities of these microfluidic
bioassay devices, we performed (i) aptamer-based sandwich immunoassays to detect
human interleukin 6 (IL6); and (ii) antibody-based sandwich immunoassays to detect
human c-reactive protein (hCRP) with a limit of detection of 4 nM, a level below the
range required for clinical screening. Lastly, the shelf-life potential of these ready-to-use
microfluidic bioassay devices was validated by effectively functionalizing the patterns
with receptors up to 3 months post-printing.
In the following chapter, we use this simple patterning technique to immobilize pro-
teins onto fused silica substrates to create truly 3D microfluidic channels. These 3D
microfluidic channels are employed to investigate the dynamics of receptor–ligand in-
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4.1 Introduction
The ability of surface-based biosensors to rapidly detect receptor–ligand binding events
at the interface between a liquid and a solid surface, is heavily influenced by three
competing transport phenomena, i.e., convection, diffusion and reaction. Depending
on the slowest phenomena dominating in the system, the microfluidic devices commonly
operate in convection-limited, diffusion-limited, or reaction-limited regimes. In static
biosensing systems, the ligand molecules that are in close proximity to the receptor-
coated surfaces, i.e., the reaction site, react with the receptors. The ligands diffuse from
the preceding layers to replenish the consumed ligands in the later layers as the reaction
proceeds. This results in the formation of a steady gradient of ligand concentrations,
where the highest ligand concentrations can be seen at a certain distance away from
the reaction site. Consequentially, the speed of the biosensor is solely determined by
the time taken for the ligand molecules to diffuse across this concentration gradient
and reach the receptor–coated surfaces, resulting in diffusion-limited receptor–ligand
binding [56, 59].
On the contrary, convection-limited receptor–ligand binding is commonly observed
in nanofluidic systems, where the biomarkers are able to diffuse to the receptor-coated
surfaces faster than they are convected through the channels, due to reduced length
scales [57]. Thesemass transport limitations contribute to the slow biomarker detection
rates in surface-based bioassay systems.
To overcome mass transport-limited receptor–ligand binding, active fluid transport
systems such as orbital mixers and microfluidic devices [71, 72] have been integrated
with biosensing surfaces in attempt to accelerate the rate of ligand transport to the
receptor-coated surface, to be faster than the rate at which ligands react with the re-
ceptors. In this scenario, the ligands that are consumed by the reaction site are steadily
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replenished by convection thereby halting the growth of the ligand concentration gra-
dient. As a result, the speed of the ligand detection is solely determined by the kinetics
of the receptor–ligand reactions, resulting in reaction-limitations [26, 58, 59].
Currently, most microfluidic systems are being designed to operate in the reaction-
limited regime, where the ligand solution is continuously flowed (i.e., convected) through
the channels to replenish the consumed ligands as they react with the receptor molecules.
But, do the previously described analytical solutions still hold for conditions where the
ligands are flowed through the channels at extremely fast flow rates?
In this chapter, we aim to answer this question by first creating novel modular
3D glass microfluidic devices that allow us to employ extremely fast flow rates with-
out channel deformations. Using these devices, we monitor the effects of fast flow
rates on the real-time binding kinetics between fluorescently-labelled receptor–ligand
immunoglobulin G (IgGs) pairs via fluorescence microscopy. We then perform simple
numerical simulations to substantiate our experimental observations. With the help of
dimensional analysis, we derive dimensionless parameters that allow us to explain our
observations by quantifying order-of-magnitude differences between competing phe-
nomena in this system, i.e., convection, diffusion and reaction. Finally, we summarize
our observations by providing design rules to support the development of fast and
sensitive microfluidic bioassay systems.
4.2 Experimental
4.2.1 Fabrication of two-part modular 3D microfluidic bioassay
devices
Computer-aided design (CAD) model
The inter-connectable modular microfluidic system consisting of two components: (1) a
solid cone and (2) a hollow 3D microfluidic channel, was designed using Rhinoceros c© 3D
modelling software (USA). The solid cone (height of 3.2 mm) was obtained by slicing
a 130 µm gap between an outer concentric cone (top surface diameter of 2.79 mm)
and the inner solid region (Figure 4.1(a)). Inversely, the hollow microfluidic region was
obtained by slicing the regions inside the microchannel boundaries (Figure 4.1(b)).
The microchannel (length of 11.4 mm, with height and width of 400 µm) was designed
to consist of a solid obstacle in the center of the channel that created a confinement
region of height 20 µm. A hollow conical cavity, whose centerline aligns with that
of the obstacle, was designed to connect with the solid cone after fabrication. Each
component was sliced into a set of well defined contour (red) and hatch lines (blue)
to complete the sliced CAD models (Figure 4.1(c-d)). The contours (20 µm intervals)
outlined the boundaries of the component surfaces and the hatches (10 µm intervals)
divided the bulk regions of the cone and microchannel into differently-sized polyhedra.
Selective laser induced etching (SLE) in fused silica substrates
The sliced CAD models of the cone and microfluidic channel were rendered in fused
silica by selective laser induced etching (SLE) using LightFab 3D printer (GmBH,
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Figure 4.1: Computer-aided design (CAD) model of the modular microflu-
idic device. Dimensional sketches of the surfaces that outline the boundaries of the
(a) cone and (b) microfluidic channel bodies. The sliced CAD models of the (c) cone
and (d) confinement region in the microfluidic channel. The sliced model is comprised
of contour lines (red), that outline the boundaries, and hatch lines (blue), that section
the cone and channel bodies into well-defined polyhedra.
Germany) [17]. The slices served as paths used by the LightFab scanner to modify
the fused silica during the printing. Finally the laser-modified regions in the bulk of
the fused silica substrate were etched by sonicating in KOH for 72 hours, at 85◦C
(100 µm/hr etch rate). During this process, the solid cone and hollow channel are
obtained by subtractive removal of the etched polyhedrons as designed in the CAD
model. The fused silica structures were washed in a sonicated milli-Q water bath at
85◦C for 1-2 hrs, to obtain the two components of the modular microfluidic device
(Figure 4.2(a-b)).
4.2.2 Immunoglobulin (IgG) bioassay using the assembled 3D
modular microfluidic device
The fabricated cones were subsequently sonicated in acetone for 30 mins and patterned
on the tips with APTES ((3-aminopropyl)triethoxysilane) by microcontact printing,
as previously described in Chapter 3 [4]. The APTES-coated cones (Figure 4.2(a))
were then linked to the receptor biomolecules via 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and N-Hydroxysuccinimide (NHS) chemistry. For the binding
kinetics studies, the cones were incubated in a PBS solution containing 10 µg/ml of
AlexaFluor R© 488 goat anti-mouse immunoglobulins (IgGs) that served as the receptor
molecules. The uncoated surfaces of the cones (all regions apart from the cone tip) were
coated with black marker ink to prevent light scattering during fluorescence microscopy
imaging. The receptor-coated cones were then connected with the conical hollow region
of the fabricated 3D microfluidic channel and sealed using Loctite 350 UV cure-adhesive
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Figure 4.2: Assembly of 3D modular microfluidic bioassay device. (a) Fused
silica cones are patterned with APTES by microcontact printing, and then sequentially
functionalized with the capture biomolecules with standard EDC–NHS chemistry. (b)
The cones are then plugged into the cavity of the 3D microfluidic device and sealed to
complete the (c) confinement region in the microfluidic device. The dark markings in
the broad regions of the receptor-coated cones are label texts embedded in the cone
bulk meant to serve as alignment marks during assembly.
(100% intensity, 10 s exposure) to complete the 3D confinement channels (Figure 4.2(b-
c)). The interior surfaces of the microchannels were blocked with 1% bovine albumin
solution (BSA) prior to binding kinetic studies to prevent non-specific adsorption of
proteins. Varying concentrations (0.125–2 µg/ml) of AlexaFluor R© 555 rabbit anti-goat
IgGs were flushed through the channels at varying flow rates (1–100 µl/min), depending
on the binding kinetics study. The median values of all data points were obtained
for 3 experimental sets, where the standard deviations are calculated to estimate the
experimental uncertainties throughout this study.
4.2.3 Image processing and analysis
The cone tip that served as the reaction site, was imaged from the bottom of the
microchannel using the Nikon Ti-E inverted epifluorescence microscope equipped with a
CCD camera (Orca Frash v4.0, Hamamatsu photonics). All binding reactions occurring
on the cone tip were imaged under a FITC or TRITC filter, at a fixed exposure time
of 6 s. For the binding kinetics studies, timelapse images were captured either at
a frame rate of 1 image/10 s or 1 image/60 s, for a total capture time of 40 mins.
The unprocessed images captured for each dataset were analyzed and processed using
MATLAB R© (Mathworks, Japan) and ImageJ (NIH, USA). The roughness (≈30 nm
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RMS) inside the microchannel cavity as a result of the SLE process, resulted in heavy
light scattering when imaged under the FITC excitation-emission spectral regime. To
avoid this issue, IgG receptor-ligand pairs were accordingly chosen to be compatible
for imaging in the TRITC excitation-emission spectral regime. Nevertheless, an image
of the PBS-filled microchannel was captured prior to flowing fluorescent IgG solutions,
to extract the intrinsic background fluorescence intensity for each experimental setup.
This background fluorescence intensity was subtracted from all subsequent fluorescent
images captured during the binding kinetics study. Following background subtraction,
the median pixel intensity per µm2 area for the selected regions of interest (ROI)
was extracted for each image and used for subsequent analyses. All data have been
graphically depicted using OriginPro2017 (OriginLab, USA). Additionally, the images
were processed post quantification to increase the contrast through linear modifications
in ImageJ for visual depiction.
4.3 Theory
4.3.1 Defining the region of interest in the microfluidic system
The 3D microfluidic device used in this study (Figure 4.2 & illustrations in Figure 4.3) is
composed of a single straight channel of width W, height H and a rectangular obstacle
(length l, width w) located in the center of the channel that creates a confinement region
of height h. This confinement region, is considered as the region of interest in this study,
where w = W . A circular reaction site with diameter d, whose center is aligned with
the center of the obstacle, is located on the top wall of the microchannel, at a height
h above the obstacle. The reaction site spans the entire width of the confinement
region. This reaction site is composed of receptors (blue spheres in Figure 4.3) that
serve to capture the target ligands. The target biomarker solution consisting of ligands
(red sticks in Figure 4.3) is flowed through the channel with an initial concentration
of C0, at a constant pressure-driven flow rate, Q. The dimensions of the fabricated
microchannels and flow rates used in this study are listed in Table 4.1.
In the region of interest, i.e., the confinement region (Figure 4.4), the width of
the obstacle is sufficiently larger than the confinement height (w=8.2h). Hence, the
flow in these channels is assumed to be unidirectional and invariant along the width
of the channel (i.e., along the z-axis). As a result, the transport phenomena in these
channels can be approximated to be 2-dimensional (2D), where the boundary effects
from the side walls of the channel are neglected. In addition, the fluid is assumed to be
incompressible and Newtonian. The flow is assumed to be axial and steady. The effects
of gravity are neglected due to the relatively small height of the confinement, and the
Table 4.1: Dimensions and flow rates used in the 3D microchannel, shown in Figure 4.3
W & w H h l d Q
(µm) (µm) (µm) (µm) (µm) (µl/min)
447.2±2.3 455.0±3.1 54.7±3.6 534.6±1.4 399.0±11.3 0 – 100
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Figure 4.3: Schematic of the microchannel cross section. (a) Bottom view and
(b) side view of the microchannel of width W, height H, confinement width w, length
l and height h, and reaction site diameter d. The reaction site, at a height h directly
above the obstacle (top channel wall), consists of immobilized receptors (blue spheres).
These molecules capture specific ligands (red sticks) flushed through the channel with
a flow rate Q. The origin of the coordinate system is placed at the center of the reaction
site, on the top wall of the microfluidic channel.
changes in physical properties of the fluids due to temperature fluctuations are assumed
to be insignificant. The micrometer-scale dimensions of the microfluidic system ensure
that the flow within the channels is laminar. The 2D channel geometry is described
by the Cartesian coordinate system, where the origin of the coordinate system is at
the center of the reaction site. A 1-dimensional (1D) immunoreaction (along x-axis,
i.e., the axial direction) occurs on the reaction site (region 4 in Figure 4.4) between
the receptors and ligands. This criterion is only valid when the ligand concentration is
assumed to be constant along the width of the confinement region.
4.3.2 Estimating the flow field in the confinement region
In accordance with the above assumptions, the flow profile of the buffer solution in the
microchannel can be described by the Hagen-Poiseuille law [73], where the fluid (i.e.,
the ligand buffer solution) velocity can be described by the Navier-Stokes equation.
Assuming the flow is steady, the equations are,
ρ(~U · ∇)~U = −∇p + µ∇2~U, (4.1)
ρ(∇ · ~U) = 0, (4.2)
where ~U(x,y)=u(x,y)êx+v(x,y)êy is the 2D fluid velocity, p is the pressure within
the flow field, and ρ and µ are the buffer solution’s density and dynamic viscosity
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Figure 4.4: Schematic of the confinement region with labelled boundaries.
The region of interest, i.e., the confinement region (solid lines) of length l and height
h, consists of the reaction site (diameter d) immobilized with receptors (blue spheres)
with a surface concentration of bmax. The ligands (red sticks) are flowed in solution
through the channel at a flow rate Q, and an initial concentration of C0, with a dif-
fusion coefficient of D. The concentration of ligands close to the reaction site is c.
The ligands react with the immobilized receptors with an association and dissociation
constant kon and koff respectively, to form the receptor–ligand complex, where the
surface concentration of the complex is bc. Dotted lines illustrate the extended regions
of the microfluidic channel outside the confinement region (height, H and length, L).
The boundaries of the system are numbered from 1-10. The origin of the coordinate
system is placed at the center of the reaction site, on the top wall of the microfluidic
channel.
respectively. As illustrated in Figure 4.3, w>>h in the confinement region, which
entails ~u(x,y)>>~v(x,y). Additionally, assuming the flow is unidirectional, ~u(x,y) can
be simplified to ~u(y) along the axial direction. The parabolic velocity profile can thus
be described as,





y(y − h)êx, (4.3)
where ∂p/∂x is the negative axial pressure gradient and êx is the unit normal
vector in the x-direction. Next, the average velocity in the confinement region uavg, is
calculated by integrating the velocity field over the confinement height. Therefore, the











This equation is substituted into equation 4.3 to obtain the expression for the
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The spatio-temporal evolution of the ligand concentration field c(x,y,t) in the confine-
ment region is governed by the additive effect of molecular diffusion and convection
due to flow, that can be described by the convection–diffusion equation:
∂c
∂t
= D∇2c − ~U · ~∇c, (4.6)
where c(x,y,t) is the ligand concentration field, and D is the diffusion coefficient of
the ligands in the buffer fluid. The boundary conditions for the ligand concentration
field are defined as:
c = C0 at surface (1) in Figure 4.4, (4.7)
~n ·D∇c = 0 at surfaces (3) and (5)-(10) in Figure 4.4, (4.8)
where ~n is defined as the unit normal vector directed out of the surface. Boundary
condition 4.7 ensures that the solution introduced into the channel has an initial ligand
concentration of C0 at the inlet, while boundary condition 4.8 imposes that no ligands
diffuse out of the channel walls.
4.3.4 Receptor–ligand reaction kinetics
When in close proximity, the ligand molecules reversibly bind to the receptor molecules
at the liquid–solid interface at the reaction site. Several reaction models have been pro-
posed to describe the receptor–ligand binding mechanisms [74, 75]. In this study, we
assume that the receptor–ligand binding reaction occurring on a solid surface is anal-
ogous to the reaction between adsorbates in a fluid and adsorbents on a solid surface.
Given this assumption, the receptor–ligand binding mechanism can be described by
the Langmuir adsorption isotherm model [76]. This model has been described to ef-
fectively generalize majority of the adsorption/desorption mechanisms in molecular
biology [58]. Specifically, the Langmuir model describes the pseudo-first order binding
reaction between the ligand in solution, and the receptor immobilized on the reaction
site surface, given that (1) the ligand molecules reversibly bind to a finite number of
receptor molecules on the reaction site, (2) one receptor molecule binds to one ligand
molecule equivalently for all binding sites under isothermal conditions, and (3) the





where kon and koff are the association and dissociation constants respectively. The
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temporal evolution of the complex concentration (bc) can be estimated as,
∂bc
∂t
= konc(bmax − bc)− koffbc, (4.10)
where, c is the concentration of ligands close to the reaction site, bmax is the surface
concentration of receptors on the reaction site and bc is the surface concentration of
receptors, bound to ligand molecules. Here, the temporal evolution of bc (∂bc/∂t) is
monitored to quantify the rate of formation of the receptor–ligand complex.
Correspondingly, the reaction–flux balance boundary condition is imposed on sur-





at surface (4). (4.11)
Equation 4.11 defines the boundary condition that describes the balance between
the diffusive flux of ligands perpendicular to the reaction site, and the binding rate of
the receptor–ligand reactions.
Table 4.2: Operational parameters employed in this study
Parameter Units Quantity Reference
ρ kg/m3 9.98× 102 [77]
µ kg/m.s 1.0× 10−3 [78]
D m2/s 44.0× 10−12 [79]
bmax moles/m2 1.0× 10−9 [57]
4.3.5 Scaling analyses
The governing equations listed in Sections 4.3.3 & 4.3.4 are non-dimensionalized to
derive approximate scaling solutions and dimensionless parameters. These scaling so-
lutions pave ways to perform comparative analyses of interdependent flow and reaction
parameters employed in this system.
Non-dimensionalized mass transport equation
Equation 4.6 is non-dimensionalized by scaling the ligand concentration by the initial
ligand concentration C0, the axial distance scaled by the diameter of reaction site (d),
transverse distances by the confinement height (h), and time by the characteristic time
(equation 4.12). At low flow rates, only those ligands that diffuse across the height of
the confinement towards the reaction site, are able to bind to the immobilized receptors.
Hence, the characteristic time that emulates this phenomenon, is the time (tD) taken
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where, Peh = Q/wD is the bulk Peclet number, which is the ratio of convective
to diffusive ligand transport within the confinement region, and β = h/d is the aspect
ratio of the confinement height to the diameter of the reaction site. As the supplied
ligands are steadily captured by the receptors at the reaction site, a steady depletion
zone with thickness δ is formed.
While Peh describes the dominance of diffusion (when, Peh << 1) versus convection
(when, Peh >> 1) of antibodies in the confinement zone at low flow rates, it does not
encapsulate the effect of linear shear flow, when extremely fast flow rates are employed
in the system.
At extremely fast flow rates, the ligands are flushed downstream before they have a
chance to diffuse across the confinement height, h. In this case, the reaction site does
not experience the effect of the full parabolic flow profile, but is most affected by the
linear flow profile (equation 4.14) up to a certain height close to its surface,





where, γ̇(y=0) is the shear rate at the reaction site (y = 0). In the case of high
local velocities, the diffusive ligand flux is independent of confinement height, but
dependent on the steady depletion zone thickness, δ. At this distance close to the
reaction site, those ligands that are convected by the linear flow across the length
(d) of the reaction site (tc = d/γ̇(y=0)δ), have just enough time to diffuse across δ to
reach the reaction site (tδ = δ2/D). This results in a new characteristic time scale (tδ)
that describes the time taken for an ligand to diffuse across the depletion zone, with
thickness δ = (dD/γ̇(y=0))1/3, at high flow rates.
By accounting for these new spatial and temporal scales arising at enhanced local
flow conditions, the convection-diffusion equation (equation 4.6) can be scaled with the

















Thus, the new non-dimensionalized expression of equation 4.6, that incorporates

























Equation 4.18 defines the local Peclet number (Peδ) in the confinement region,
relating the bulk Peclet number (Peh) and the aspect ratio of the confinement region
(β). Peδ enables us to quantify the competition between diffusive transport of the
ligands and transport of ligands by linear convective flow, in the vicinity of the reaction
site.
Additionally, the boundary conditions 4.7 & 4.8 are non-dimensionalized using the
same scaling analyses as described above to obtain:













= 0 at surfaces (3) and (5)-(10). (4.20)
Non-dimensionalized receptor–ligand reaction kinetic equation
The governing equation for receptor–ligand reaction kinetics (equation 4.10) can be
non-dimensionalized to derive a dimensionless parameter that describes the balance
between the transport and reaction time scales. Here, the concentration of bound
receptors (bc) is scaled by the surface concentration of immobilized receptors (bmax),
c is scaled by the initial ligand concentration C0, and time is scaled by the time taken




























where Dadiffusion = C0konδ2/D and Daoff = δ2koff/D are the Damkohler numbers
that represents the ratio of the reactive flux to the diffusive flux for the association and
dissociation reactions respectively.
Correspondingly, the boundary condition 4.11 is non-dimensionalized using the






at surface (4), (4.24)
where, Peδ = γ̇(y=0)d2/D in equation 4.18, and, φ = C0δ/bmax. Furthermore, with
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Here, equation 4.25 is the dimensionless reaction–flux balance boundary condition,
where the dimensionless quantity φ is termed as the “binding fraction”. This dimen-
sionless quantity can be used to ensure that the surface concentration of immobilized
antigens (bmax) is always higher than C0δ.
4.4 Numerical Simulation
The evolution of the depletion zone (thickness of δ) with sequentially increasing Peδ in
the confinement region was modelled using the finite element COMSOL Multiphysics R©
software (COMSOL, Sweden) algorithms. The device geometry and domains were
defined according to Figure 4.4 using the dimensions listed in Table 4.1. The compu-
tational mesh consists of 166826 free triangular domain elements with minimum and
maximum element sizes of 0.0682 µm & 5.91 µm, with a maximum element growth
rate of 1.08 µm. In addition to the free triangular domains, the boundaries of the de-
vice geometry were emphasized using the boundary layer mesh, with a boundary layer
stretching factor of 1.05 for a total of 9 layers, where the thickness of the first layer
was defined to be 0.5 µm. The edges of the geometry were refined with the in-built
corner refinement algorithm, where the minimum angle between boundaries was set to
be 240◦, with an element size scaling factor of 0.25. The mesh quality was inspected
until data convergence was observed using the optimized mesh. Figure 4.5 demon-
strates that the final mesh consists of optimal elements within the device geometry
(green domains indicate the best quality of 1).
The microchannel boundaries were divided into 10 surfaces as illustrated in Fig-
ure 4.4, where the reaction site was defined by surface 4. The bulk laminar flow field
Figure 4.5: Image demonstrating the mesh quality of the COMSOL model.
The computational mesh for the defined device geometry was constructed with a mix-
ture of free triangular domains and boundary layers. The geometry edges were refined
using the corner refinement algorithm, until a quality of 1 (green domains) was ob-
tained. The mesh quality of 1 indicates the presence of optimal elements in the mesh
domain.
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and transport of diluted ligand species at steady state were modelled by solving the di-
mensional Navier-Stokes equations (equations 4.1 & 4.2) coupled with the dimensional
convection-diffusion equation (equations 4.6). The assumptions listed in Section 4.3.1
were imposed for all the simulations. The boundary and initial conditions were imposed
based on equations 4.7 & 4.8. An initial ligand concentration (C0) of 6.67 mol/m3 was
used for all the simulations, to be consistent with the experimental C0 employed in
this study. The receptor–ligand binding reaction was modelled on surface 4, using the
dimensional Langmuir adsorption model (equation 4.9 and boundary condition 4.11).
As the dissociation constant koff < 10−5 s−1 has been reported for moderate affinity
IgG–IgG binding reactions [80, 81], the “rapid irreversible surface reactions” module
(i.e., koff = 0) was chosen as a limiting case for the COMSOL simulations. The so-
lutions of the velocity and concentration fields were obtained using the Generalized
Minimal Residual iterative solver and the in-built PARDISO course solver. The raw
data from the simulations were extracted and graphically represented using Origin-
Pro2017 (OriginLab, USA).
4.5 Results and discussion
4.5.1 Defining local Peclet number (Peδ) to characterize ligand
transport in the 3D microfluidic channels
Microfluidic systems have been employed to actively transport ligands to the receptor-
coated reaction surfaces, in an attempt to overcome mass transport limitations and
achieve kinetic enhancement of receptor–ligand interactions at liquid–solid interfaces.
In this section, we use scaling analysis to characterize the ligand transport within the
fabricated 3D microfluidic channels. Furthermore, we describe the mechanisms that
drive the targeted delivery of ligand molecules to the reaction site, placed in parallel
to the flow direction.
In this study, the 3D modular microfluidic device is composed of two interlocking
components: (1) a solid fused silica cone (Figure 4.2a), whose tip is coated with re-
ceptor molecules that are covalently linked to APTES patterned on the tip surface
via a previously described microcontact printing method [4], and (2) a straight 3D
microchannel embedded in fused silica, composed of a rectangular obstacle positioned
at the center of the channel. The region above the obstacle is hollowed out conically to
allow subsequent locking with the complimentary fused silica cone (Figure 4.2b-c), to
create a confinement region of height h above the obstacle (Figure 4.6a). This confine-
ment region encapsulating the receptor-coated cone tip that serves as the reaction-site,
is defined as the region of interest in this study.
A ligand solution consisting of fluorescently-labelled immunoglobulins (IgGs) (red
sticks in Figure 4.6a), suspended in PBS (phosphate buffered saline), is flowed through
the microchannel at varying flow rates, Q (table 4.1). The reaction site is coated with
complimentary fluorescent IgGs (blue spheres in Figure 4.6a) that serve as receptors to
capture the ligand IgGs. The details of the IgG pair have been listed in Section 4.2.2.
In accordance with the assumptions listed in Sections 4.3.1 & 4.3.2, the flow conditions
that enabled the ligand IgG solution to attain fully developed laminar flow profiles
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Figure 4.6: Ligand transport through the 3D microfluidic channel. (a) De-
scriptive stereomicroscopic cross-section image of the assembled 3D modular microflu-
idic bioassay device, with channel height H and confinement height h. Ligands (red
sticks) are flowed through the microchannel with a flow rate Q and react with the
receptors (blue spheres) patterned on the reaction site. (b) Reynolds number (Re) and
entrance length (Le) plotted as a function of axial flow velocity (uh). (c) Schematic
illustrating the steady ligand depletion layer formed in the confinement region of the
device. (d) Local Peclet number (Peδ = γ̇(y=0)d2/D) plotted against the shear rates
(γ̇(y=0)) experimentally investigated in this study.
in the vicinity of the reaction site were identified and employed for this study. As
seen in Figure 4.6b, the Reynolds numbers (Re, characterized as Re = ρuhh/µ) were
observed to be below the critical Reynolds number (Recrit), where, Recrit is defined as
the Re at which the entrance length (Le = 0.13Re) is equal to the distance between
the starting points of the obstacle and the reaction site (measured to be 50 µm).
Re < Recrit is indicative of fully developed laminar flow [82] for flow velocities between
10−1 < uh < 10
5 µm/s. Due to the potential complications arising from transient flow
effects on the receptor–ligand kinetics, faster flow velocities (uh > 105 µm/s), were not
employed in this study as the flow profile is not fully developed near the reaction site
when Re > Recrit.
At extremely low Re (Re < 10−4), purely diffusive transport of ligand IgGs to the
reaction site is observed, as described by the low Peclet numbers (Peh << 1). Here,
Peh = Q/wD is defined as the ratio of convective to diffusive ligand transport, obtained
from the non-dimensionalized convection–diffusion equation (equation 4.13), described
in Section 4.3.5. Diffusion-driven ligand transport at Peh << 1 is not considered in
this study. Instead, we focus our investigations on purely convection dominant ligand
transport. In particular, we experimentally investigate the receptor–ligand kinetics at
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Peh >> 10
2, achieved at Re > 10−1.
As the ligand IgGs are convected through the confinement region, those molecules
close to the reaction site are gradually consumed as a result of the binding reaction
with the receptor IgGs. As a consequence, the ligand IgG concentration close to the
reaction site (c) is much lower than the bulk ligand IgG concentration (C0), creating a
steady ligand concentration boundary layer above the reaction site. In this study, the
boundary layer is termed as the depletion zone, whose thickness is defined as δ. The
schematic in Figure 4.6c illustrates the depletion zone created above the reaction site.
At Peh >> 102, the ligand IgGs above δ are swept away without ever interacting with
the reaction site. As a result, the ligand convection in the bulk of the confinement
region is no longer a dominating factor in this system. On the contrary, the local
convection in the vicinity of the reaction site plays a significant role in the transport
of ligands to the surface.
While the bulk Peh fails to account for the effect of local effects, the dimensionless
local Peclet number, Peδ = γ̇(y=0)d2/D, allows us to quantify the dominance of local
convective flow versus diffusion, in the transport of ligand IgGs to the reaction site
(derived in Section 4.3.5). As depicted in Figure 4.6d, convection dominated ligand
transport is observed with increasing shear rate γ̇(y=0), where 103 < Peδ < 108. The
effect of enhanced convection-driven ligand transport on the receptor–ligand reaction
kinetics will be experimentally investigated for 105 < Peδ < 108 in the following
sections.
4.5.2 Homogeneous binding of ligands across reaction site at
high Peδ
While enhanced receptor–ligand binding kinetics is an anticipated outcome of enhanced
convective flows, we observed an interesting influence of Peδ on the homogeneity of lig-
and binding across the reaction site. To investigate this effect, we divided the centerline
of the reaction site into 7 sequential regions, as illustrated by 7 different symbols in
Figure 4.7a. The temporal evolution of ligand IgG binding (for C0 = 6.67 mol/m3)
on the reaction site was monitored at these 7 regions of interest (ROIs) individually,
starting from time, t = 0 min, up to t = 40 min (red fluorescent images in Figure 4.7a).
The binding kinetics at the reaction site was investigated using the analytical solu-
tion of the Langmuir adsorption isotherm (equation 4.10). This analytical solution is
obtained under the assumption that the binding reaction is the rate-limiting process at
high Peδ flows employed in these sets of experiments (where, 105 < Peδ < 108). Under
this assumption, the ligand IgG concentration (c) close to the reaction site approaches
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Figure 4.7: Influence of Peδ on homogeneity of ligand ligand across reaction
site. (a) The fluorescence micrographs show the reaction site before and after capture
of ligand IgGs (red), at t = 0 min and t = 40 min, respectively. White circles outline
the reaction sites and dotted lines mark the channel boundaries. Symbols marked on
the images indicate the 7 regions of interest (ROI) distributed across the centerline of
the reaction site, employed in the following graphs. (b) Each graph depicts the evolu-
tion of fB (fraction of bound receptors) as a function of time for the 7 defined ROIs,
for experimentally increasing Peδ. Each profile is fitted with equation 4.29 to extract
the fraction of bound receptors at equilibrium, fB(eq). (c) Normalized fluorescence in-
tensities of immobilized receptors, extracted from the 7 ROIs, plotted as a function
of position on reaction site, for varied Peδ. Inset fluorescence micrograph depicts the
surface of reaction site coated with receptor IgGs (green). (d) fB(eq) plotted as a func-
tion of position on reaction site for varied Peδ. Dotted lines are apparent linear fits
meant to serve as trendlines, and error bars are within the symbols for all displayed
data (n = 3).
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where, bc(t) is the number of receptor IgGs bound with ligand IgGs at a given time
(t), KD = koff/kon is the equilibrium dissociation constant and τR = (konC0 + koff )−1
is the time taken for the reaction to equilibriate. Here, fB is the fraction of bound
receptor IgGs. fB is experimentally measured by calculating the median fluoresence
ratios and standard deviations (n = 3) of captured ligand IgGs (red) and receptor IgGs
(green) from the respective fluorescence micrographs (Figure 4.7a).
Additionally, the fraction of receptor IgGs bound with ligand IgGs at equilibrium








The final equation describing the temporal evolution of fB can be re-written as:
fB = fB(eq)(1− e−(t/τR)). (4.29)
Equation 4.29 is used to fit the experimental data to track the evolution of fB at
the 7 defined ROIs, plotted in Figure 4.7b for increasing Peδ. At Peδ = 2.7× 105, the
leading edge of the reaction site (i.e., point 1 in Figure 4.7a) was seen to equilibriate
faster than the trailing edge (i.e., point 7 in Figure 4.7a). In addition, the varied
saturation profiles for the 7 ROIs indicate that the concentration of captured ligand
IgGs at equilibrium, is largest at the leading edge (indicated by the saturation of fB
at 0.54), and decreases towards the trailing edge. This decreasing tendency in both
saturation speed and captured ligand IgG concentration with increasing distance from
the reaction site-leading edge was observed to diminish with increasing Peδ.
To eliminate the contribution of inhomogeneities arising from the receptor IgG im-
mobilization, the normalized median fluorescence intensities extracted from the 7 ROIs
were plotted against the position on the reaction site for each tested experimental con-
dition (105 < Peδ < 108). As seen in Figure 4.7c, the normalized fluorescence intensity
is invariant across all positions on the reaction site centerline, for all of the tested ex-
perimental conditions. Additionally, the error bars are within the symbols for all data
points, thereby demonstrating minimal experimental variation in fluorescence intensi-
ties across different data sets (n = 3). This proves that the apparent inhomogeneity
in ligand binding observed at low Peδ is not a result of inhomogeneous distribution of
receptors on the reaction site.
To analytically quantify the concentration of captured ligand IgGs at equilibrium,
we extracted the fraction of bound receptor IgGs at equilibrium, fB(eq) from each
fitted curve for the respective ROI from the plots in Figure 4.7b. As observed in
Figure 4.7d, fB(eq) linearly decreases with distance from the leading edge of the reaction
site at Peδ = 2.7× 105. With increasing Peδ, fB(eq) becomes more uniform across the
reaction site, indicating that the homogeneity of ligand binding across the reaction site
is influenced by the inhomogeneity of ligand IgG transport to the reaction site at low
Peδ. These results indicate that binding uniformity can be achieved by increasing the
local Peclet number, i.e., by increasing the flow rates (Q) and/or decreasing the size of
the reaction site (d).
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4.5.3 Uniform ligand flux across reaction site at high Peδ
At extremely high flow rates, the ligand IgGs that diffuse to the receptors across the
depletion zone (at time tδ), are replenished by the carrier fluid flowed through the con-
finement region (at time tc). The balance of diffusive and enhanced convection-driven
ligand transport is defined by the local Peclet number, where Peδ = γ̇(y=0)d2/D. In
this scenario, the growth of the depletion zone is halted at a steady state height δ de-
pending on the rate of ligand replenishment. Additionally, past research has predicted
that δ increases monotonically with increasing axial distance [59]. We hypothesize
that this axial variation of δ leads to a heterogeneous delivery of ligand IgGs across
the reaction site, ultimately influencing the homogeneity of ligand binding as observed
in Section 4.5.2.
To validate this hypothesis, we performed numerical simulations using COMSOL,
to examine the spatial evolution of δ across the reaction site for 2.7× 103 ≤ Peδ ≤
2.7× 107. The device architecture, computational mesh geometries and the model
definitions are elaborated in Section 4.4, which are consistent with the experimental
conditions. Briefly, the 2-dimensional (2D) transport of ligand IgGs (where, C0 =
6.67 mol/m3) was modelled by solving the coupled Navier-Stokes and convection-
diffusion equation (equations 4.1, 4.2 & 4.6). The receptor–ligand IgG binding reaction
was modelled on the reaction site, using the Langmuir adsorption model (equation 4.9
and boundary condition 4.11). As a limiting case, we modelled rapid irreversible sur-
face reactions in COMSOL owing to the low rates of dissociation observed for IgG–IgG
reactions (koff < 10−5 s−1) [80, 81].
Figure 4.8a shows the 2D concentration profiles of ligand IgGs plotted against
position along channel height, for low (Peδ = 2.7 × 103), moderate (Peδ = 2.7 ×
105), and enhanced convective flows (Peδ = 2.7× 107). The gradient of concentration
profiles illustrate the depletion zone formed as a result of ligand IgG consumption at
the reaction site. As seen in Figure 4.8a(i), a large depletion zone is formed in the
confinement region, that extends downstream into the outlet channel. However, the
depletion zone starts shrinking with increasing Peδ, illustrating that the ligand IgGs
are efficiently replenished by the flowing fluid, following consumption at the reaction
site.
Next, we investigated the influence of Peδ on the axial variation of depletion zone
thickness across the reaction site. For this purpose, we plotted δ for varying positions
across the reaction site at 50 µm intervals. The trailing and leading edges of the
reaction site were omitted to avoid complications arising from edge effects. As seen in
Figure 4.8b, δ was seen to increase with increasing distance from the leading area of
the reaction site for 2.7× 103 ≤ Peδ ≤ 2.7× 105. With further increase in Peδ, the
depletion zone was observed to be uniform across the reaction site, as illustrated by the
invariance of δ on varying positions on the reaction site. The uniformity of δ implies
that relatively equal concentrations of ligand IgGs are delivered to the entire surface
of the reaction site. This subsequently results in a more homogeneous ligand binding.
These results validate the hypothesis that the homogeneous ligand binding observed in
Figure 4.7 is achieved when there is homogeneous ligand transport across the reaction
site at large Peδ.
In addition, we observed a power law relationship between the mean depletion zone
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Figure 4.8: Relationship between Peδ and δ as observed by numerical simu-
lations. (a) COMSOL simulations depicting the ligand depletion layer profiles in the
confinement region of the 3D microchannel, for (i–iii) increasing Peδ. The gradient of
ligand concentration (c) in the depletion zone is illustrated by the color scale, where
the maximum concentration (black) is 6.67 mol/m3. (b) The depletion zone thickness
at different positions of the reaction site centerline, plotted for increasing Peδ. Dotted
lines are drawn to serve as linear trendlines for the plotted data. (c) The evolution of
δmean with increasing Peδ is described by the power law, δmean ≈ n(Peδ)α (black sym-
bols). Correspondingly, the Sherwood number (Sh) evolves with Peδ, as Sh ≈ (Peδ)α
(blue symbols). The trendlines depict the power laws for the respective plots.
thickness (δmean) and Peδ:
δmean ≈ d̂× (Peδ)α, (4.30)
where, α = −0.33 and d̂ = d± 232 µm. It is worth noting that the the variation of
±232 µm from the analytically derived power law that defines d̂ = d [59], was observed
to be a result of the axial variations of δ across the reaction site.
Finally, we estimate the influence of Peδ on the ligand IgG transport flux using
a dimensionless flux parameter, the Sherwood number (Sh). Here, Sh is defined as
the ratio of diffusive (JD) and enhanced convective flow-driven (Jδ) ligand flux rate
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where, D is the ligand IgG diffusivity, C0 is the initial ligand concentration, d
is the length of the reaction site and δ is the depletion zone thickness. Figure 4.8c
demonstrates that the Sherwood number (Sh) increases with increasing Peδ with the
power law:
Sh ≈ Peδα, (4.32)
where, α = 0.33, as predicted by the analytical solution proposed by Squires et. al.,
[59]. The increase in Sh at Peδ > 105 indicates that the replenishment of the ligand
IgGs as they are consumed is controlled by local convection dominating close to the
reaction site.
In the following sections, we perform in-depth investigations to understand how the
receptor–ligand reaction kinetics transforms with enhanced convection-driven ligand
IgG transport (Sh > 101 and Peδ > 105).
4.5.4 Estimating the kinetic constants of the receptor–ligand
IgG reaction
As the ligand IgGs diffuse across the depletion zone (δ) and reach the reaction site, they
react with the receptor IgGs in a reversible fashion. This binding reaction is analytically
described using the Langmuir adsorption model (equation 4.9) (refer to Section 4.5.2).
To extract the kinetic constants, kon and koff , we monitored the receptor–ligand IgG
binding kinetics at Peδ = 2.7 × 107, at sequentially increasing initial ligand IgG con-
centrations (0.42 < C0 < 13.33 nM). Figure 4.9a depicts the evolution of fluorescence
intensity ratios over a period of 40 mins for each C0, plotted as steps in the graph. Here,
the fluorescence ratio is calculated as Ired/(Ired + Igreen), where Ired and Igreen are the
median fluorescence intensities of the reaction site coated receptors bound with ligands
(red) and coated with unbound receptors (green), respectively (see Figures 4.7a & c
for reference).
We then temporally normalized the fluorescence intensity ratios for each C0 by
subtracting the fluorescence ratio at all time intervals (t) for a given C0, with the fluo-
rescence ratio at time t = 40 mins for the preceding C0. This normalized fluorescence
intensity ratio ultimately allowed us to estimate the fraction of bound receptors (fB)
for each case. The temporal evolution of fB is plotted in Figure 4.9b for each C0. Each
data set was fitted with equation 4.29 to extract the reaction equilibrium time, τR.
We plotted 1/τR as a function of C0 to yield a linear trend, as observed in Fig-
ure 4.9c. Finally, the kinetic constants kon and koff were obtained from the slope and
intercept of the following linear fit equation:
τR = (konC0 + koff )
−1. (4.33)
For the receptor–ligand IgG pairs used in this study, we obtained a kon of 3.90 ×
105 M−1s−1 and a koff of 2.86× 10−4 s−1, at Peδ = 2.7× 107. These kinetic constants
are in agreement with the constants described in literature [81] for a moderate affinity
polyclonal IgG pair. These kinetic constants are employed to investigate the receptor–
ligand IgG reaction kinetics at 2.7× 105 < Peδ < 2.7× 107, in the following sections.
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Figure 4.9: Ligand–receptor binding kinetics. (a) Evolution of fluorescent in-
tensity ratio with time, depicting the binding of ligand IgG with receptor IgG for
Peδ = 2.7× 107. Each step of the curve indicates the IgG–IgG binding profile for seri-
ally increasing initial ligand IgG concentrations (C0). (b) Fraction of bound receptor
sites (fB) plotted as a function of time for the respective C0 introduced into the channel
sequentially. Each data set is fitted with equation 4.29 to extract reaction equilibrium
time (τR). (c) The reciprocal of τR is plotted against C0 to obtain a linear profile,
where the slope and intercepts of the curve generate the reaction rate constants, kon
and koff , respectively. The grey line depicts the linear fit with equation 4.33. Error
bars depicted in these figures are estimated from the standard deviations obtained for
n = 3 datasets.
4.5.5 Re-examining the Damkohler number (Da) using kinetic
scaling analysis
From the kinetic equation of the Langmuir adsorption model (equation 4.10), we know
that the rate at which the ligands are captured by the receptors is heavily influenced
by 3 important factors: (1) the kinetic constants (kon and koff ) that define the affinity
between the receptor and ligand IgGs, (2) the surface density of the receptors on the
reaction site (bmax), and (3) the concentration of ligand IgGs close to the reaction site
(c). Of these limiting factors, kon, koff can be tailored by bioengineering techniques and
bmax can be optimized by surface chemistry techniques. Assuming that high affinity
receptors are coated on the reaction site at high surface densities, the concentration of
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ligands close to the reaction site (c) becomes the sole limiting factor that controls the
speed of the receptor–ligand reaction.
As described in previous literature, convective replenishment of the consumed lig-
and IgGs can play a dominant role in maintaining a steady supply of c close to the
reaction site [59, 71]. Here, the balance between the ligand–receptor reaction rate
and the rate of replenishment of c can be studied with the help of an important di-
mensionless parameter, the Damkohler number (Da). This dimensionless parameter
naturally arises as a result of the nondimensional parametrization of the Langmuir
kinetic equation (equation 4.10).
In Section 4.3.5, we employ conventionally used spatial and temporal scales as de-
scribed by Gervais et. al. [58], and Squires et. al. [59] to deriveDadiffusion = C0konδ2/D.
Here, we assumed that the dominant time scale that influences the receptor–ligand re-
action kinetics, is the time required for the ligand IgG to diffuse across the depletion
zone (tδ = δ2/D). As a result of this assumption, the time was scaled with tδ to obtain
the nondimensionalized time, t∗ = t/tδ = Dt/δ2.
Dadiffusion describes the balance between the three important phenomena compet-
ing for dominance at the reaction site: (1) receptor–ligand reaction kinetics (described
by C0 & kon), (2) diffusion (described by D) and (3) enhanced convection-driven ligand
IgG transport (described by δ). As per the definition, Dadiffusion >> 1 implies that
the time taken for the receptor–ligand reaction to reach equilibrium is determined by
the time taken for the ligand IgGs to reach the reaction site. In this scenario, slow
replenishment of c leads to a reduction in the ligand IgG capture rate. On the con-
trary, Dadiffusion << 1 implies that the equilibrium time is solely determined by the
receptor–ligand reaction kinetics. In this ideal case, the ligand IgGs close to the reac-
tion site are constantly replenished by the flowing carrier fluid, such that the capture
of ligand IgGs is no longer affected by mass transport limitations.
As presented in Table 4.3, Dadiffusion << 1 for Peδ > 2.7 × 105, where C0 =
13.33 nM, kon = 3.90× 105 M−1s−1 and koff = 2.86× 10−4 s−1 for the receptor–ligand
IgG pair used in this study. These low Damkohler numbers indicate that the ligand
IgGs are efficiently replenished by the convecting flow as they are consumed, thereby
removing mass transport limitations in this system.
To further strengthen this argument, we quantified the average concentration of
ligand IgGs (c̄) present in a 1 µm thick region close to the reaction site, from the
numerical simulations elaborated in Section 4.5.3. We then plotted the ratio of c̄/C0 as
a function of Peδ in Figure 4.10a. We observed an increasing c̄/C0 ratio with increasing
Table 4.3: Damkohler numbers employed in this study
Peδ Dadiffusion Dakinetic
(γ̇(y=0)d2/D) (C0konδ2/D) (bmaxkonδ/D)
2.70× 105 1.02× 10−2 1.17× 10−1
2.70× 106 1.13× 10−3 3.87× 10−2
1.35× 107 4.56× 10−4 2.46× 10−2
2.70× 107 3.57× 10−4 2.18× 10−2
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Peδ. In particular, we noticed that c̄ approaches C0 (i.e., c̄/C0 = 1) at Peδ > 1.4×107,
indicating that the ligand IgG concentration close to the reaction site is the same as
the bulk ligand IgG concentration. This proves that the ligand IgGs are effectively
replenished by the flowing carrier fluid as they are depleted by the reaction site, during
strong convective flow.
Considering these observations, the time taken for the ligand IgGs to diffuse across
δ is no longer the dominant time scale in this scenario, thereby invalidating the as-
sumption employed in the nondimensionalization of the temporal scale (equation 4.21)
used to derive Dadiffusion. To account for this deviation observed under enhanced con-
vective flows, we hypothesize the speed of the ligand IgG detection is determined solely
by the time taken for a ligand IgG molecule to react with a receptor IgG molecule at
Figure 4.10: Ligand–receptor binding described by kinetic scaling analysis.
(a) Ligand concentration close to reaction site (c̄) extracted from the numerical sim-
ulations is scaled by the initial ligand concentration (C0), and plotted as a function
of Peδ. Closed symbols mark the experimentally investigated data and extended data
points are plotted as open symbols. (b) Dimensionless bound receptor concentration
(bc∗ = bc/bmax) plotted as a function of dimensionless time (t∗ = konC0t). (c) Dimen-
sionless reaction equilibrium time (τ ∗) and dimensionless equilibrium bound receptor
concentration (b∗eq) plotted as a function of Peδ. (d) Dimensionless binding equilibra-
tion time (τ ∗) normalized by dimensionless reaction time (τR∗) plotted as a function of
kinetic Damkohler number (Dakinetic). The blue line depicts the limit where τ ∗ = τ ∗R.
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an “on-rate” of kon. This results in a new dimensionless time scale, t∗ = t/ton = C0kont.
Using this new temporal scale and the same spatial scales listed in equation 4.21,
equation 4.10 is non-dimensionalized to obtain:
∂b∗
∂t∗
= c∗(1− b∗)−K∗Db∗, (4.34)
where, K∗D = koff/(konC0) is the non-dimensionalized kinetic dissociation coeffi-
cient.
Subsequently, the reaction-flux balance boundary condition (equation 4.11) is non-







, t∗ = C0kont, (4.35)








where, the Dakinetic = bmaxkonδ/D is the kinetic Damkohler number. As seen in
Table 4.3, Dakinetic << 1 for Peδ > 2.7×105, indicating that mass transport conditions
are overcome under these flow conditions. We employed bmax = 1 × 10−9 moles/m2
(refer to Table 4.2), based on the assumption that 10% of receptor IgGs are able
to capture ligand IgGs, when immobilized using APTES chemistry on glass surfaces
(Section 4.2.2) [57].
It should be emphasized that both Dakinetic and Dadiffusion provide the same infor-
mation in this study. However, we propose that Dakinetic is more suitable to character-
ize the balance of receptor–ligand reaction rate and ligand transport rate, in scenarios
where ligand transport is no longer a restriction, i.e., at Peδ >> 105.
In addition, as c = C0 at Peδ >> 105, equation 4.34 can be analytically solved to










where, b∗c and b∗eq are the dimensionless bound receptor concentration at time=t∗
and at equilibrium, respectively. τ ∗R is the dimensionless equilibrium reaction time.
Equation 4.38 allows us to estimate the time taken for a given receptor–ligand reaction
to reach equilibrium, based on the kinetic constants of the given receptor–ligand pair.
Here, K∗D can be estimated as koff/(konC0).
Assuming that the speed of ligand detection is not influenced by mass transport
limitations, the receptor–ligand IgG reaction can be estimated to reach equilibrium
at a dimensionless equilibrium reaction time (τ ∗R) of 0.90, for an initial ligand IgG
concentration of 13.33 nM, and kinetic constants kon = 3.90× 105 M−1s−1 and koff =
2.86× 10−4 s−1.
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To identify the time taken for receptor–ligand IgG reaction to equilibriate (τ ∗) at
varying Peδ, we plotted the evolution of b∗c as a function of t∗ for 2.7 × 105 < Peδ <
2.7× 107, in Figure 4.10b, for C0 = 13.33 nM. The data was fitted with equation 4.37
to extract τ ∗ and b∗eq for each Peδ. As observed in Figure 4.10c, τ ∗ decreases for
increasing Peδ (black squares). In addition, the reactions were seen to equilibriate at
increasing equilibrium concentrations (b∗eq) for increasing Peδ (green open triangles).
These results demonstrate that enhanced convective ligand IgG transport enhances the
receptor–ligand IgG reaction rate, thereby decreasing ligand IgG detection time.
Finally, we closely examine the influence of Dakinetic on τ ∗ in order to ascertain if
this observed enhancement of receptor–ligand IgG reaction rate at increasing Peδ is a
result of decreasing mass transport restrictions under these conditions. For this purpose
we plotted the ratio of τ ∗/τ ∗R as a function of Dakinetic. As seen in Figure 4.10c, τ ∗
approaches τ ∗R (τ ∗/τ ∗R = 1) at Dakinetic << 10−2, illustrating that the rate of ligand IgG
delivery perfectly balances the receptor–ligand reaction, thereby reducing any delays
in ligand IgG detection time that may arise from mass transport limitations.
In other words, the time taken for receptor–ligand IgG reaction to equilibriate under
enhanced convective flows reaches the molecular reaction equilibrium time at Peδ >>
107. These results imply that the speed of the receptor–ligand reaction is no longer
limited by the low abundance of ligand IgGs close to the vicinity of the reaction site,
in this scenario. In other words, mass-transport limitations are terminated under these
conditions, allowing for faster receptor–ligand reactions. Thus, rapid ligand detection
can be achieved for any biomolecular system, by simply designing microfluidic devices
that create strong convective flows given that, Peδ >> 107 for Dakinetic << 10−2 .
4.5.6 Development of glass microfluidic bioassay devices with
enhanced ligand detection speed and sensitivity
In the previous sections in this Chapter, we demonstrated that the homogeneity and
“speed” of the receptor–ligand binding reactions can be enhanced by amplifying local
ligand transport via convection. In this section, we explore the effect of Peδ on the
ligand detection “sensitivity” of the 3D modular microfluidic devices. For this purpose,
we monitored the real-time binding kinetics between the model receptor–ligand IgGs
for a period of 20 mins for varying ligand concentrations (0.4 nM < C0 < 13.33 nM),
at Peδ = 2.7× 106 & 2.7× 107.
In a typical bioassay system, it is more desirable to detect the reacting ligands
as soon as the detector is able to capture the reaction signal, rather than waiting
for the receptor–ligand reaction to equilibriate. In these cases, the ligand detection
speed and sensitivity, i.e., the “detection efficiency”, strongly depends on (1) the total
number of ligand molecules that bind at any given time, and (2) the ability of the
detector to detect the capture ligands at that given time. To quantify the “detection
efficiency” of the fluorescence-based 3D microfluidic bioassay devices, we first monitored
the evolution of normalized median fluorescence intensity as a function of C0 and Peδ,
at a detection time of 10 mins. As seen in Figure 4.11a, the linear ligand IgG detection
range starts at a lower C0 for Peδ = 2.7 × 107 (red shaded region), when compared
to Peδ = 2.7 × 106 (blue shaded region). Although the width of the linear ranges
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Figure 4.11: Influence of Peδ on limit of detection of ligand IgGs. (a) Lig-
and IgG concentration (C0) plotted as a function of normalized median fluorescence
intensity for Peδ = 2.7× 106 & 2.7× 107, at time, t = 10 mins. The linear ranges are
indicated by the red (Peδ = 2.7× 107) and blue (Peδ = 2.7× 106) shaded regions. The
limit of detection (LoD) is estimated from the linear fit and equation 4.39 for each Peδ.
R2 = 0.99 for the linear fit and the error bars (n = 9) are within the symbols. (b) The
variations in LoD as a function of detection time are plotted following calculations for
the same C0 range for Peδ = 2.7× 107 and Dakinetic = 2.2× 10−2. The dotted spline is
used to illustrate the general trend of the data. (c) Fluorescence micrographs depicting
the reaction site after capture of ligand IgGs at 10 mins, for the C0 range used in the
LoD calculations in (b). The dotted lines illustrate the microchannel boundaries and
the white circles delineate the reaction site.
were observed to be similar, the starting concentration for the linear range was seen
to increase by a factor of 2 when Peδ was reduced by one order of magnitude. These
observations indicate that the total number of ligand IgGs that reach the reaction site
in 10 mins is lower for Peδ = 2.7 × 106 than Peδ = 2.7 × 107. Furthermore, the
depletion zone thickness δ was estimated to be a factor of 2 smaller for Peδ = 2.7×107
(δ=2.4 µm) than Peδ = 2.7 × 106 (δ=4.5 µm), as seen in the numerical simulations
described in Section 4.5.3. As a consequence, at lower Peδ, (1) the ligand IgGs have to
diffuse across a larger distance to reach the reaction site, and (2) the consumed ligand
IgGs are replenished at a slower rate close to the reaction site. These two factors
cumulatively both decrease the total number of ligand IgGs detected at any given time
and increase the ligand detection time at low Peδ.
In addition, the “sensitivity” of the 3D microfluidic bioassay device was quantified
by calculating the limit of detection (LoD) from the linear fit Figure 4.11a and the
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following equation [83]:
LoD = 3.3(SD(int)/s), (4.39)
where, SD(int) and s are the standard deviations of the y-intercept and the slopes of
the linear fit, respectively (red and blue solid lines in Figure 4.11a). At a detection time
of 10 mins, the LoD was seen to be ≈5-fold lower for Peδ = 2.7×107 (LoD=11.63 pM),
when compared to that of Peδ = 2.7× 106 (LoD=52.62 pM). This reduction in LoD at
high Peδ further demonstrates the ability of enhanced local convective flows to improve
the ligand detection “sensitivity” of microfluidic bioassay systems.
Upon further examinations, we observed that low concentrations of ligand IgGs
(C0 < 1 nM) could be fluorescently detected within 5 mins using the 3D modular
microfluidic bioassay system, at Peδ = 2.7 × 107. As illustrated in Figure 4.11b,
the LoD of the system was quantified to be highest at a detection time of 3 mins
(LoD=43.33 pM) and steadily decreased upto 10 mins (LoD=11.63 pM). A gradual
increase in LoD was observed at detection times larger that 15 mins. This gradual
increase is attributed to the (1) decreasing linearity of the receptor–ligand kinetic curve
as the reaction gradually approaches equilibrium (τR ≈ 7 mins), and (2) increasing
errors in median fluorescence intensity due to formation of aggregates at large Peδ.
Consequently, these results demonstrate that high “detection efficiency” fluorescence
based microfluidic bioassay systems can be fabricated to detect a wide range of ligand
IgG concentrations (Figure 4.11c) “rapidly” (detection time of 10 mins) and with high
“sensitivity” (LoD=11.63 pM), using the proposed design principles (i.e., Peδ >> 107
for Dakinetic << 10−2).
4.5.7 Collective influence of Peδ on receptor–ligand reaction ki-
netics
The design rules proposed in the previous sections are in agreement with the rules
proposed by previous authors [26, 58, 59], where the rules were all based on a very im-
portant assumption: the maximum attainable reaction speed in any system is defined
by the molecular properties of the receptor–ligand pairs, vis-à-vis the kinetic constants.
These assumptions were based on another important assumption that the kinetic con-
stants, i.e., kon and koff , are invariant of external factors such as flow, temperature,
ionic strength, etc.
Given that the addition of variable ionic strength and temperature would add fur-
ther complexity to the models used to describe microfluidic bioassay systems, we wanted
to explore the effects of a less complex variable i.e., shear rate, on the variance of re-
action kinetic constants. In addition to being an easily altered variable, shear rate
(γ̇(y=0)) is already incorporated in the analytical model by means of the local Peclet
number, Peδ.
Using the same set of IgGs as described above, we performed receptor–ligand reac-
tion kinetic experiments, at two different Peδ. Here, we plotted the temporal change
of fB (fraction of bound receptors) in Figures 4.12a(i) & b(i) for variable C0, at
Peδ = 2.7 × 106 and Peδ = 2.7 × 107, respectively. Each data set was fitted with
equation 4.29 to extract the reaction equilibrium time, τR. We extracted the kinetic
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constants kon and koff from the slope and intercept of the linear fit in the plots of 1/τR
vs C0, for Peδ = 2.7×106 and Peδ = 2.7×107, as observed in Figures 4.12a(ii) & b(ii).
For the same receptor–ligand IgG pairs used in this study, we observed a significant
difference in kon and koff values for the two Peδ. As seen in Table 4.4, while the
changes in kon with increasing Peδ were observed to be minute, an order-of-magnitude
increase in koff was observed with a proportional order-of-magnitude increase in Peδ.
These results indicate that while the association reaction between the receptor
and ligand remain unchanged, the dissociation reaction is accelerated with increasing
local convection close to the reaction site surface. Prior literature reported similar
Figure 4.12: Influence of Peδ on kinetic constants. Fraction of bound receptor
sites (fB) plotted as a function of time for the respective C0 introduced into the channel
sequentially, for (a)(i) Peδ = 2.7 × 106 & (b)(i) Peδ = 2.7 × 107. Each data set is
fitted with equation 4.29 to extract reaction equilibrium time (τR). The reciprocal
of τR is plotted against C0 to obtain a linear profile for (a)(ii) Peδ = 2.7 × 106 &
(b)(ii) Peδ = 2.7 × 107. Here, the slope and intercepts of the curve generate the
kinetic constants, kon and koff , respectively. The grey line depicts the linear fit with
equation 4.33.
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Table 4.4: Kinetic constants observed at variable Peδ
Peδ kon koff
(γ̇(y=0)d2/D) (M−1s−1) (s−1)
2.70× 106 4.23× 105 6.14× 10−5
2.70× 107 3.90× 105 2.86× 10−4
observations in studies focussed on understanding the effect of shear stress on cell–
receptor adhesion in biological systems [84, 85] and receptor–ligand reactions in the
BIAcore biosensing system [86].
However, the analytical models that have been derived to describe the receptor–
ligand binding reactions in microfluidic systems, fail to account for this proportional
relationship between koff and Peδ. By solely relying on the design rules that suggest the
fabrication of fast flow systems, we are neglecting the effects of enhanced dissociation
of captured ligands at increasing shear rates. While this could be seen as a potential
drawback of enhanced convective flows, it is worth noting that the dissociated ligands
are also simultaneously replenished as a consequence of the fast transport, thereby
creating a self-sustaining feedback loop.
Although the effects of enhanced koff at large Peδ may not have a detrimental
impact on the speed of the receptor–ligand sensing systems, it plays a major role in
applications where microfluidic systems are exploited to quantify the kinetic constants
[87, 88]. Due to the high variability of koff at high flow rates, utmost care must be
taken before interpreting the kinetic parameters. While this observation was noted
only at high flow rates, it is unclear if the variability of the kinetic constants can be
prevented by employing slow flow rates. Additionally, further research is required to
be able to include this flow rate-dependent variation of koff in the analytical models
used to describe microfluidic receptor–ligand binding reactions. Furthermore, these
preliminary observations open doors for further investigations in the future.
4.6 Conclusions
In this chapter, we described a novel method to fabricate modular 3D microfluidic bioas-
say devices using selective laser etching process enabled by the LightFab 3D printer.
The fabricated device consists of an embedded 3D microfluidic channel that locks with
a conical component patterned with receptor molecules using the previously described
microcontact printing strategy described in Chapter 3.
Using these devices, we studied the binding kinetics between model receptor–ligand
IgG molecules under enhanced convective flows. We proposed scaling solutions to
present important dimensionless parameters that could be used to study the balance
of competing phenomena in this system. These parameters are listed in Table 4.5.
We observed that homogeneous ligand binding across the reaction site can be
achieved by creating a thin and uniform depletion layer with enhanced local convection
(i.e., Sh > 101 & Peδ >> 105). Additionally, we demonstrated that the mass transport
limitations are overcome with enhanced convective ligand transport, thereby enhancing
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Table 4.5: Dimensionless parameters employed in this study
Dimensionless parameter Definition Significance
β = h/d dimensionless aspect ratio confinement height
reaction site length
Peh = Q/wD bulk Peclet number convection ratediffusion rate
Peδ = γ̇(y=0)d
2/D local Peclet number shear rate
diffusion rate
Sh = d/δ Sherwood number diffusive flux rate
convective flux rate
Dadiffusion = C0konδ
2/D diffusion Damkohler no. reaction rate
mass transport rate
Dakinetic = bmaxkonδ/D kinetic Damkohler no. reaction ratemass transport rate
K∗D = bmaxkonδ/D dimensionless dissociation constant
ligand dissociation rate
ligand association rate
the speed of the receptor–ligand binding reaction. We subsequently proposed kinetic
scaling analysis method to derive Dakinetic, that can be used to characterize enhanced
convective flow receptor–ligand reaction systems more reliably than the conventional
Dadiffusion obtained by diffusion scaling analysis. Using the observed results, we pro-
posed design rules that enabled the fabricate enhanced microfluidic receptor–ligand
IgG bioassay systems with a limit of detection of 11.63 pM (1.75 ng/ml) and detection
speed of 10 mins. Finally, we presented preliminary data that shows the increase in
dissociation constant, koff at high flow rates.
These results not only provides comprehensive analyses to allow users to design
rapid biosensing systems for different biomolecules (not limited to IgGs), but also pave
way for further interesting investigations in the future.
Conclusions and Future Perspectives
The aim of this thesis was to propose design principles for the development of rapid,
sensitive and user-friendly point-of-care (POC) disease diagnostic devices. To this end,
a manually-operated proof-of-concept POC testing device was developed by integrating
novel fluid handling modules with simple polymethyl methacrylate (PMMA) microflu-
idic bioassay devices. To tune the speed and sensitivity of the developed microfluidic
bioassay systems, flow-dependent kinetic enhancement investigations were carried out.
This concluding section summarizes the findings reported in each chapter of this thesis.
Chapter 2
A simple and rapid method to fabricate efficient PMMA microfluidic bioassay
devices at high-throughput was proposed in Chapter 1. First, we exploited radio-
frequency (RF) air plasma to generate functional groups that enabled the subsequent
covalent coupling of receptor proteins on PMMA surfaces. We observed that the plasma
energy had a direct influence on the density of polar and hydrophobic groups generated
on the PMMA surfaces. A maximum density of carboxyl groups (COOH) could be
obtained on the PMMA surface when exposed to 27 kJ of air plasma. At these opti-
mum conditions, the COOH-rich PMMA surfaces showed the highest affinity towards
green fluorescent protein (GFP), when coupled via EDC–NHS mediated chemistry.
Additionally, high GFP surface densities could be obtained with lower intial con-
centrations of GFP at a neutral pH of 7.4. The immobilized GFP molecules retained
their bio-functionalities, depicted by their ability to serve as receptors that captured
GFP-specific ligand immunoglobulin G molecules (IgGs). This demonstrated function-
alization strategy is applicable to a wide range of receptor molecules, namely, IgGs,
streptavidin and major outer membrane proteins (MOMP) of Chlamydia trachoma-
tis. Finally, microfluidic antibody assay devices were fabricated to detect clinically
significant concentrations of Chlamydia trachomatis specific antibodies.
While polymeric substrates are most commonly used to manufacture microfluidic
bioassay devices at large-scale, the inert nature of these materials has resulted in the
need to use stringent surface functionalization strategies for the immobilization of re-
ceptor molecules. The fabrication strategy discussed in this chapter paves way to create
high-throuphput PMMA microfluidic bioassay using rapid and scalable, yet controlled
bio-functionalization methods, without causing any changes in the functionalities of




In Chapter 2, the developed PMMA microfluidic bioassay devices were integrated
with a modular Fluid Handling Device (FHD) to serve as a “proof-of-concept” manually
operated point-of-care (POC) testing device for the detection of Chlamydia trachomatis
specific IgGs.
The manually-powered FHD module allowed the user to process a deposited sample
by mixing it with on-board stored reagents, filtering the mixture and delivering it
to subsequent modules. The FHD was developed to be used as a stand-alone fluid
processing system or used to couple with the microfluidic bioassay chip for disease
detection. The integrated system with coupled FHD and PMMA microfluidic bioassay
devices enabled the detection of Chlamydia trachomatis specific IgG from a buffer-
based blood mimic sample, with a limit of detection of 1.05 µg/ml within 15 mins.
The high limit of detection was observed to be a result of suboptimal design of the
developed PMMA microfluidic bioassay devices. Nevertheless, the existing prototype
was shown to be completely integrated, easy to use, hand-held, manually powered and
disposable, with the potential of serving as a point-of-care testing device.
In the following chapters, we investigated the parameters that influenced the roots of
these issues. Here, we focussed on developing glass-based microfluidic bioassay systems
(1) to eliminate contributions of fluorescence scattering, (2) to allow for fabrication of
robust microfluidic devices (3) that served as a better model system to study receptor–
ligand binding kinetics at high flow rates.
Chapter 4
In this chapter, we demonstrated a 2-step microcontact printing approach to en-
capsulate covalently immobilized receptor molecules within glass-based microfluidic
bioassay devices. First, micropatterns of (3-aminopropyl)triethoxysilane (APTES), an
amine –NH2 terminated silane, were transfered from an elastomeric polydimethylsilox-
ane (PDMS) stamp to a hydrophilic glass surface, by microcontact printing. During
this process, we replaced conventional solvents (toluene and ethanol) with water to
limit the diffusion of APTES within the PDMS stamp, thereby allowing us to create
micro- and nanoscale microcontact printed features. These APTES patterned surfaces
were observed to be stable for up to 3 months post printing.
The APTES patterned substrates were bonded to open-ended microfluidic chan-
nels to complete the device. Receptor molecules such as IgGs and DNA aptamers
were coupled to APTES within the channels using standard EDC–NHS chemistry or
BS3 chemistry. Using dispensing robots and microfluidic channel networks, we demon-
strated the ability of functionalizing multiple kinds of receptor molecules within one
device using just on stamping process. Finally, by coupling the receptor molecules
immediately prior to use, the bio-functionalities of the receptors were observed to be
well preserved, while maintaining their ability to bind to biomarkers such as C-reactive
protein (CRP) and interleukin 6 (IL6).
Chapter 5
In the final chapter, we used this simple patterning technique to immobilize recep-
tor IgGs onto fused silica substrates to create truly 3D microfluidic channels. These
3D microfluidic channels were fabricated using a relatively new selective laser etching
process enabled by the LightFab 3D printer. We used these devices to experimentally
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investigate the influence of enhanced convective flows on the binding kinetics between
complimentary receptor–ligand IgGs.
We re-examined the scaling analyses proposed in prior literature to experimentally
validate the assumptions made for the scaling processes. First, we defined the local
Peclet number Peδ = γ̇d2/D that helped us characterize the balance between local
convection and diffusion driven transport of ligands within the microfluidic devices.
At Peδ >> 105, homogeneous binding of ligands across the reaction site surface was
observed. This observation was explained to be a result of the uniform thinning of
the depletion zone, (ligand concentration gradient created as a result of steady binding
with receptors at the reaction site) at high Peδ. Additionally, under these conditions,
a steady replenishment of ligands close to the reaction site was observed to enhance
the receptor–ligand reaction kinetics.
Using kinetic scaling analysis, we proposed the use of the kinetic Damkohler number
(Dakinetic = bmaxkonδ/D) to characterize the balance between the rates of receptor–
ligand binding and enhanced convection-driven ligand replenishment. Finally we pro-
posed that rapid ligand detection can be achieved for any biomolecular system by
designing microfluidic devices with Peδ >> 107 for Dakinetic << 10−2. Using the pro-
posed design rules, we fabricated high sensitivity (LoD=1.75 ng/ml) and high speed
(detection speed of 10 mins) fluorescence-based glass microfluidic IgG-detection sys-
tems. By applying these design principles to the integrated FHD–microfluidic POC
system, we envision the creation of highly efficient point-of-care testing systems in
the future. In addition, we observed an apparent increase in the kinetic dissociation
constant (koff ) of receptor–ligand IgG reactions at increasing Peδ. If proven defini-
tively, these observations have immense implications in applications where microfluidic
systems are used to quantify kinetic constants in biomolecular systems.
The results presented in this thesis not only serve as design references for the fabri-
cation of rapid and sensitive point-of-care testing systems, but also present interesting
observations that open doors for further comprehensive studies in the future. In ad-
dition, the novel 3D modular glass microfluidic devices developed in this thesis could
serve as robust platforms to obtain new insights in transport phenomena and reaction
kinetics at small length scales.
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